Last reviewed · How we verify
BA3021
BA3021 is a small molecule targeting the PI3K pathway.
BA3021 is a small molecule targeting the PI3K pathway. Used for Relapsed or refractory acute myeloid leukemia.
At a glance
| Generic name | BA3021 |
|---|---|
| Sponsor | Canadian Cancer Trials Group |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BA3021 works by inhibiting the PI3K enzyme, which is involved in cell signaling pathways that regulate cell growth and survival. This inhibition can lead to the death of cancer cells. By targeting the PI3K pathway, BA3021 aims to prevent cancer cell growth and proliferation.
Approved indications
- Relapsed or refractory acute myeloid leukemia
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (PHASE2)
- A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (PHASE2)
- CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |